Orforglipron vs Tesofensine
A side-by-side research comparison of Orforglipron and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Orforglipron | Tesofensine |
|---|---|---|
| Full name | Orforglipron (Oral Non-Peptide GLP-1 Agonist) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | ~550 Da | 329.4 Da |
| Half-life | 25-60 hours | 8-10 days |
| Bioavailability | Moderate-High (oral) | High (oral ~93%) |
| Typical dose | 12-45 mg | 0.25-0.5 mg |
| Frequency | Once daily | Once daily |
| Route | Oral | Oral |
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.